Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review
Telitacicept holds promise as a potential second-line therapy for refractory MN when conventional treatments prove ineffective. However, due to the current lack of robust evidence supporting its use in IMN, further research is warranted to establish its clinical efficacy and safety.
Authors
- Yongzhi Huang (ORCID: https://orcid.org/0000-0002-2503-1589)
- Shu‐Cheng Chen (ORCID: https://orcid.org/0000-0001-6771-9050)
- Zhen Qu (ORCID: https://orcid.org/0000-0002-4455-8466)
Institutions
- Shaoxing Second Hospital (CN)
- The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fmed.2025.1571616
- Citations
- 4
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 5.72